Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment
Authors:
- Jing FeiJFJing Fei
- Li-Wen QiLQLi-Wen Qi
- Yuan LiuYLYuan Liu
- Min ShuMSMin Shu
- Wen-Qiang MoWMWen-Qiang Mo
Open Access
- 15 April 2025
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 17 (4)
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Transarterial chemoembolization (TACE) combined with percutaneous radiofrequency ablation (RFA) has emerged as a promising treatment strategy for patients with unresectable HCC. AIM To evaluate the effectiveness and safety of TACE combined with RFA compared to TACE alone in the management of primary HCC. METHODS A comprehensive retrospective analysis was conducted at our institution from January 2020 to January 2024, involving 106 patients diagnosed with intermediate to advanced-stage HCC. Patients were divided into two groups: Those receiving TACE alone (n = 56) and those undergoing combined TACE and RFA therapy (n = 50). Treatment efficacy was assessed based on tumor response rates, serum alpha-fetoprotein (AFP) levels, and survival outcomes. Statistical analyses, including χ 2 tests and Kaplan-Meier survival analysis, were performed to compare the outcomes between the two groups. RESULTS The TACE + RFA group demonstrated significantly higher rates of complete response (15 vs 4, P < 0.01) and partial response (23 vs 15, P = 0.046) compared to the TACE group. Conversely, the TACE group exhibited higher rates of stable disease (25 vs 7, P < 0.01) and progressive disease (12 vs 5, P < 0.01). Serum AFP levels decreased over time in the TACE + RFA group, while they increased in the TACE group. Survival analysis revealed superior survival outcomes in the TACE + RFA group, with higher survival rates and a prolonged median survival time compared to the TACE group. CONCLUSION The combination of RFA with TACE could offer enhanced treatment response and prolonged survival in patients with primary HCC compared to TACE alone. These findings might support the adoption of multimodal therapeutic approaches, emphasizing the importance of personalized treatment strategies in the management of HCC.Keywords
This publication has 30 references indexed in Scilit:
- Hepatocellular Carcinoma: a Narrative Review on Current Knowledge and Future ProspectsCurrent Treatment Options in Oncology, 2023
- Transarterial chemoembolisation for very early and early stage hepatocellular carcinoma: single-centre experienceClinical Radiology, 2022
- Hepatocellular CarcinomaClinics in Liver Disease, 2022
- Hepatocellular CarcinomaCritical Care Nursing Clinics of North America, 2022
- Radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilusAbdominal Radiology, 2021
- Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched studyAbdominal Radiology, 2021
- Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma – A meta-analysisEuropean Journal of Surgical Oncology, 2020
- Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score AnalysisJournal of Vascular and Interventional Radiology, 2019
- Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Hepatocellular Carcinoma in the Caudate LobeCardioVascular and Interventional Radiology, 2018
- Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current statusCancer Letters, 2016